ArticleAddiction (Abingdon, England)2024
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.
Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials.JAMA psychiatry · 2026Pooled it
- Gender differences in the impact of psychological distress on methamphetamine use disorder outcomes and treatment effect.Addiction (Abingdon, England) · 2026Pooled it
- Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.Drug and alcohol dependence · 2026Trial
- Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.JAMA psychiatry · 2026Trial
- Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial.Addiction (Abingdon, England) · 2025Trial
- A single-blind, randomized, controlled contingency management trial on physiological indices and biomarkers of cardiovascular health in people with cocaine use disorder.Drug and alcohol dependence · 2025Trial
- Influence of cocaine use reduction on markers of immune function.Journal of neuroimmunology · 2024Trial
- Harm reduction-focused behavioral activation for people who inject drugs: Mixed methods outcomes from a pilot open trial.Journal of substance use and addiction treatment · 2024Trial
- Examining cocaine use reductions and long-term outcomes in two clinical trials of continuing care for cocaine dependence.Journal of substance use and addiction treatment · 2024Trial
- What Dose of Methamphetamine Do Regular Consumers Use Daily? Estimating Oral Amphetamine Milligram Equivalents.Journal of addiction medicine · 2026Article
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.BMJ open · 2026Article
- The Diagnosis and Treatment of Stimulant-Related Emergencies.Deutsches Arzteblatt international · 2025Review
- World Health Organization risk drinking level reductions as treatment outcomes in PTSD and substance use disorder trials.Drug and alcohol dependence · 2025Article
- Effects of Dictyophora polysaccharide on cerebellar Purkinje cell degeneration in a chronic alcohol mouse model.Animal models and experimental medicine · 2025Article
- Beyond frequency of use: Exploring additional metrics for quantifying cocaine use and their relation to life functioning and treatment outcome.Journal of substance use and addiction treatment · 2025Article
- Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study.JMIR research protocols · 2025Article
- Fentanyl Polysubstance Use Patterns and Their Associations With Hepatitis C Virus, Skin and Soft Tissue Infections, and Non-Fatal Overdose Among People Who Inject Drugs in New York City.Drug and alcohol review · 2025Article
- Sex-dependent modulation of behavioral allocation via ventral tegmental area-nucleus accumbens shell circuitry.NeuroImmune pharmacology and therapeutics · 2025Article
- Substance use negatively impacts change in reinforcement during the year following substance use treatment.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Article
- An exploration of desired abstinent and non-abstinent recovery outcomes among people who use methamphetamine.Harm reduction journal · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsTotal abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. We aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder.
designWe conducted a secondary analysis of a pooled dataset of 13 RCTs. SETTING AND
participantsParticipants were individuals seeking treatment for cocaine or methamphetamine use disorders (N = 2062) in a wide range of treatment facilities in the United States. MEASUREMENTS: We validated reduced stimulant use against a set of clinical indicators drawn from harmonized measurements, including severity of problems caused by drug use, comorbid depression, global severity of substance use and improvement, severity of drug-seeking behavior, craving and high-risk behaviors, all assessed at the end of the trial, as well as follow-up urine toxicology. A series of mixed effect regression models was conducted to validate reduction in frequency of use against no reduction in use and abstinence.
findingsMore participants reduced frequency of primary drug use than achieved abstinence (18.0% vs. 14.2%, respectively). Reduced use was significantly associated with decreases in craving for the primary drug [60.1%, 95% confidence interval (CI) = 54.3%-64.7%], drug seeking behaviors (41.0%, 95% CI = 36.6%-45.7%), depression severity (39.9%, 95% CI = 30.9%-48.3%), as well as multiple measures of global improvement in psychosocial functioning and severity of drug-related problems, albeit less strongly so than abstinence. Moreover, reduced use was associated with sustained clinical benefit at follow-up, as confirmed by negative urine tests (adjusted odds ratio compared with those with no reduction in use: 0.50, 95% CI = 0.35-0.71).
conclusionReduced frequency of stimulant use appears to be associated with meaningful improvement in various clinical indicators of recovery. Assessment of reduced use, in addition to abstinence, could broaden the scope of outcomes measured in randomized controlled trials of stimulant use disorders and facilitate the development of more diverse treatment approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.